Toll-interacting protein may affect doxorubicin resistance in hepatocellular carcinoma cell lines

Basit Öğe Kaydı
dc.authoridBARIŞ, Elif/0000-0001-6838-7932
dc.authoridAtabey, Nese/0000-0003-4966-2980
dc.authoridKoc, Ahmet/0000-0003-3484-2137
dc.authoridDemir, Ayse Banu/0000-0003-4616-8151
dc.authorwosidBARIŞ, Elif/HPF-4375-2023
dc.authorwosidAtabey, Nese/A-1853-2018
dc.contributor.authorDemir, Ayse Banu
dc.contributor.authorBaris, Elif
dc.contributor.authorKaner, Umay Bengi
dc.contributor.authorAlotaibi, Hani
dc.contributor.authorAtabey, Nese
dc.contributor.authorKoc, Ahmet
dc.date.accessioned2024-08-04T20:54:39Z
dc.date.available2024-08-04T20:54:39Z
dc.date.issued2023
dc.departmentİnönü Üniversitesien_US
dc.description.abstractBackgroundLiver cancer is the third leading cause of cancer-related deaths worldwide, and hepatocellular carcinoma (HCC) is the most common type of liver cancer. Transarterial interventions are among the chemotherapeutic approaches used in hardly operable regions prior to transplantation, and in electrochemotherapy, where doxorubicin is used. However, the efficacy of treatment is affected by resistance mechanisms. Previously, we showed that overexpression of the CUE5 gene results in doxorubicin resistance in Saccharomyces cerevisiae (S. cerevisiae). In this study, the effect of Toll-interacting protein (TOLLIP), the human ortholog of CUE5, on doxorubicin resistance was evaluated in HCC cells to identify its possible role in increasing the efficacy of transarterial interventions.Methods and resultsThe NIH Gene Expression Omnibus (GEO) and Oncomine datasets were analyzed for HCC cell lines with relatively low and high TOLLIP expression, and SNU449 and Hep3B cell lines were chosen, respectively. TOLLIP expression was increased by plasmid transfection and decreased by TOLLIP-siRNA in both cell lines and evaluated by RT-PCR and ELISA. Cell proliferation and viability were examined using xCELLigence and MTT assays after doxorubicin treatment, and growth inhibitory 50 (GI 50) concentrations were evaluated. Doxorubicin GI 50 concentrations decreased approximately 2-folds in both cell lines upon silencing TOLLIP after 48 h of drug treatment.ConclusionsOur results showed for the first time that silencing TOLLIP in hepatocellular carcinoma cells may help sensitize these cells to doxorubicin and increase the efficacy of chemotherapeutic regimens where doxorubicin is used.en_US
dc.description.sponsorshipScientific and Technological Research Council of Turkiye (TUBITAK) [119Z221]en_US
dc.description.sponsorshipThis work was supported by the Scientific and Technological Research Council of Turkiye (TUBITAK) (Grant number 119Z221 given to A.B.D.)en_US
dc.identifier.doi10.1007/s11033-023-08737-2
dc.identifier.endpage8563en_US
dc.identifier.issn0301-4851
dc.identifier.issn1573-4978
dc.identifier.issue10en_US
dc.identifier.pmid37644370en_US
dc.identifier.scopus2-s2.0-85169058905en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage8551en_US
dc.identifier.urihttps://doi.org/10.1007/s11033-023-08737-2
dc.identifier.urihttps://hdl.handle.net/11616/101550
dc.identifier.volume50en_US
dc.identifier.wosWOS:001063923000009en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofMolecular Biology Reportsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectHepatocellular carcinomaen_US
dc.subjectToll-interacting proteinen_US
dc.subjectDoxorubicinen_US
dc.subjectCancer drug resistanceen_US
dc.titleToll-interacting protein may affect doxorubicin resistance in hepatocellular carcinoma cell linesen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu